AltaRex Phase IIb ovarian cancer data

AltaRex (TSE:AXO; ALXFF) said its OvaRex anti- CA125 antibody did not meet the primary endpoint of a 40% difference in median time to disease relapse (TTR) compared to placebo in a Phase IIb trial in 345 patients with metastatic late-stage ovarian cancer. The trial was run in the U.S. and Canada. The company said that many Canadian OvaRex patients had risk factors for early relapse, and that randomization to OvaRex and placebo in the Canadian arm may not have been balanced for such risk factors. ...